Aldosterone is a steroid hormone produced primarily by the adrenal cortex that plays a central role in regulating sodium balance, potassium excretion, and blood pressure. When aldosterone levels are chronically elevated—or when its effects are inappropriately amplified—patients can develop hypertension through sustained renal sodium retention, expanded intravascular volume, and vascular remodeling. This mechanistic pathway is clinically important because not all high blood pressure is driven by the same biology. In particular, a subset of patients with hard-to-treat (resistant) hypertension may have an aldosterone-mediated cause that is not identified through routine evaluation.
In physiology, aldosterone binds to mineralocorticoid receptors in principal cells of the collecting duct. Activation increases sodium reabsorption via epithelial sodium channels and enhances potassium and hydrogen secretion through potassium channels and proton pumps. Net effects include volume expansion and changes in systemic vascular resistance. Aldosterone also has direct cardiovascular and renal effects beyond volume: it promotes inflammation, oxidative stress, and fibrosis, contributing to endothelial dysfunction, left ventricular hypertrophy, and chronic kidney disease. These downstream processes can worsen outcomes even when blood pressure is only partially controlled.
Clinically, the term “aldosterone excess” encompasses several conditions, but the most emphasized cause is primary aldosteronism, typically due to unilateral adrenal adenoma or bilateral adrenal hyperplasia. Less commonly, aldosterone may be elevated due to secondary causes such as renal artery stenosis, which stimulates renin and thereby increases aldosterone production. Regardless of etiology, the hallmark is inappropriate aldosterone activity relative to sodium status and renin physiology.
A key concept is that resistant hypertension may unmask underlying mineralocorticoid-driven disease. Resistant hypertension generally refers to blood pressure that remains above target despite adherence to at least three antihypertensive agents of different classes (including a diuretic), or controlled blood pressure requiring four or more medications. In such patients, aldosterone excess should be considered because standard regimens may not adequately counter mineralocorticoid receptor signaling. Evidence from clinical research suggests that elevated aldosterone levels may be more common than previously thought among patients with hard-to-treat hypertension, with studies estimating that a meaningful minority may have aldosterone-driven pathology.
Because aldosterone testing is not routinely performed for every patient with hypertension, clinicians often rely on a targeted diagnostic approach. Screening commonly uses the aldosterone-to-renin ratio (ARR) measured under standardized conditions. Interpretation requires careful attention to medications and physiologic variables that can distort results. For example, mineralocorticoid receptor antagonists, diuretics, beta blockers, and other agents can shift renin and aldosterone concentrations; hypokalemia can also suppress aldosterone in some contexts. Many protocols recommend correcting potassium, reviewing medication timing, and adjusting interacting therapies when feasible, ideally under specialist guidance.
Confirmatory testing may follow a positive ARR, including saline infusion testing, oral sodium loading, fludrocortisone suppression, or captopril challenge. The goal is to demonstrate autonomous aldosterone secretion that fails to suppress appropriately. After biochemical confirmation, subtype evaluation distinguishes unilateral from bilateral disease. Imaging with adrenal CT can identify structural lesions, but it may miss microadenomas or detect incidentalomas. Therefore, adrenal venous sampling is often used in surgical candidates to determine unilateral aldosterone production more accurately.
Treatment aligns with etiology. For unilateral primary aldosteronism, adrenalectomy can offer the potential for cure or marked improvement, with benefits including reduced cardiovascular risk over time. For bilateral disease or when surgery is not preferred, long-term pharmacotherapy with mineralocorticoid receptor antagonists is standard. Spironolactone and eplerenone block aldosterone’s receptor-mediated effects, reducing sodium retention and mitigating aldosterone-related vascular and renal injury. Dosing is titrated to blood pressure response and electrolyte stability, with monitoring for hyperkalemia and renal function changes.
Beyond disease-specific therapy, patients require comprehensive cardiovascular risk management: lifestyle modification, adherence support, secondary cause review, and appropriate selection of complementary antihypertensive agents. Particularly in aldosterone-mediated hypertension, optimizing diuretic strategy and ensuring adequate blockade of mineralocorticoid signaling can be decisive.
In summary, aldosterone excess represents a biologically plausible and potentially underrecognized driver of hypertension, especially in those with resistant disease. Recognizing the role of aldosterone helps clinicians move from a one-size-fits-all approach toward mechanism-based care, using ARR screening, confirmatory testing, and targeted treatment to improve blood pressure control and reduce long-term cardiovascular and renal complications. Source: WebMD
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
